On December 4, Pfizer India became the first pharmaceutical company to seek emergency use authorization of its Covid-19 Vaccine from the Drug Controller General of India (DCGI) in India after it secured clearance in the United Kingdom and Bahrain. Pfizer Vaccine candidate has shown about 95% efficacy against the coronavirus during the clinical trial data analysis.
According to a source, “Pfizer India has submitted an application on December 4 to the DCGI seeking Emergency Use Authorisation (EUA) for its covid-19 vaccine.” They also added that “the firm has submitted the Emergency Use Authorisation (EUA) in the form of CT-18 to grant permission for Pfizer-BioNTech’s COVID-19 mRNA vaccine BNT162b2.
Pfizer India, in its application, has sought permission from the Drug Controller General of India, to import the vaccine for sales and distribution across the country.
On December 2, the United Kingdom became the first country to permit the Pfizer-BioNTech Covid-19 vaccine. The UK Regulator Medicines and Healthcare products Regulatory Agency (MHRA)has granted a temporary authorization for the emergency use of the Covid-19 vaccine which is developed by Pfizer. The country has already ordered over 40 million doses of the vaccine to provide it to 20 million population.
While on the other side, Bahrain finally permitted the emergency use of the vaccine on Friday. On Friday, during an all-party meet, Prime Minister Narendra Modi cited experts to say that India could have the first Covid-19 vaccine in weeks and that eight vaccines will be manufactured in India.
Meanwhile, the government official said that the big challenge which may arise is in the delivery of vaccine in India as vaccine requires extremely low temperature about minus 70 degrees for its storage.
The global pharma major said in a statement that” During this pandemic phase, Pfizer will supply this vaccine only through government contracts based on agreements with respective government authorities and following regulatory authorization or approval”.
As the cases in India have reached over 96 lakh including over 4 lakh active cases and 91 lakh recoveries, by seeing this scenario, the authorization of this vaccine in India seems like a silver lining to end this global pandemic.
Follow our Health & Care Section to read more about such topics.
See more TSA Mag stories on GoogleAdd us as a preferred source and our stories will show up more often in your Top Stories.
Add The Second Angle as a preferred source on Google
